The Latest Breaking News from Crispr rapeutics

Inverse predicts the biggest innovations of 2023, including wins in renewable energy, electric vehicles, and biotechnology.

Cathie Wood makes big bets on potential huge winners. But Ark Invest's top 10 holdings, including Tesla and Roku, tumbled in 2022.

Vertex Pharmaceuticals is the IBD Stock of the Day as the global biotech company climbs above its 50-day moving average.

 

Ten years ago this week, Jennifer Doudna and her colleagues published the results of a test-tube experiment on bacterial genes. When the study came out in the journal Science on June 28, 2012, it did not make headline news. In fact, over the next few weeks, it did not make…

Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

A Relative Strength Rating upgrade for Crispr Therapeutics shows improving technical performance.

Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics are trading up 3.81% over the last 24 hours, at $62.23 per share.

Upgrades